Vitamin D Status in Inflammatory Bowel Disease

Summary

Inflammatory bowel disease (IBD), comprising crohn's disease (CD) and ulcerative colitis (UC), is a a chronic, relapsing-remitting systemic disease. Vitamin D is a secosteroid hormone that possesses immunomodulatory properties and has been demonstrated to potentially influence inflammatory bowel disease (IBD) pathogenesis and activity.

Conditions

• Vitamin D Deficiency
• Inflammatory Bowel Diseases

Interventions

DIAGNOSTIC_TEST

serum total 25 hydroxycholecalciferol 25(OH) vitamin D

Quantitative measurement of serum total 25(OH) vitamin D by ELISA. Fasting (6-8 hours), venous blood samples(10ml) are collected from participants in the morning and after centrifugation, the serum are preserved in the deep freezer at -20 c. Serum levels will be determined by using commercially available kits.

DIAGNOSTIC_TEST

complete blood count (CBC)

for measurement of hemoglobin level and white blood cell count percent of neutrophils ,lymphocytes and esoinphils

DIAGNOSTIC_TEST

serum calcium level

measurement of total calcium level after correction with albumin level as it is closely related to vitamin d with its effects on its level

DIAGNOSTIC_TEST

erythrocyte sedimentation rate (ESR)

it is an indicator of activity in inflammatory bowel disease

DIAGNOSTIC_TEST

C-reactive protein (CRP)

it is an indicator for increased possibility of infections

DIAGNOSTIC_TEST

serum creatinine

for assessment of renal function

DIAGNOSTIC_TEST

serum albumin level

for possibility of malabsorbtion in patients with inflammatory bowel disease

DIAGNOSTIC_TEST

seum alanine aminotransferase

for assessment of liver function

DIAGNOSTIC_TEST

serum potassium level

indicator for hypokalemia increased in patients with diarrhea as result of inflammatory bowel disease

DIAGNOSTIC_TEST

serum phosphurus level

measurement of phosphurus level as it is closely related to vitamin d with its effects on its level

Sponsors & Collaborators

• Assiut University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

20 Years

Max Age

60 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2018-04-30

Primary Completion

2019-04-30

Completion

2019-06-30

Countries

• Egypt

Study Locations